Zobrazeno 1 - 10
of 41
pro vyhledávání: '"C. R. Lazarus"'
Publikováno v:
Nuclear Medicine Communications. 18:776-784
The long-term precision of chromium-51 ethylenediamine tetraacetic acid ( 51 Cr-EDTA) measurements of glomerular filtration rate (GFR) was evaluated in a retrospective study of data obtained over a 12 year period. Each GFR measurement was derived fro
Autor:
J. Singh, Furn F. Knapp, C. R. Lazarus, K. Reghebi, Philip J. Blower, A P Callahan, Simon Clarke
Publikováno v:
Nuclear Medicine Communications. 14:197-203
The preparative conditions for 186Re(V)DMSA and 188Re(V)DMSA (DMSA = meso-dimercaptosuccinic acid), beta-emitting radiopharmaceuticals that have been shown to localize in medullary thyroid carcinoma, require modification depending on the amount of ca
Publikováno v:
Nuclear Medicine Communications. 11:343-360
Technetium-99m (99Tcm)(V) dimercaptosuccinic acid (DMSA) is a new tumour imaging agent which has been used to evaluate squamous carcinoma (SCC) of the head and neck. This study evaluated the pharmacokinetics and biodistribution of 99Tcm(V)DMSA in pat
Publikováno v:
Nuclear Medicine Communications. 11:111-120
Technetium-99m (99Tcm) (v) dimercaptosuccinic acid (DMSA) is a new tumour imaging agent which has been used to image squamous cell carcinoma (SCC) of the head and neck. This study was undertaken to compare planar versus SPECT 99Tcm (v) DMSA scintigra
Publikováno v:
Nuclear Medicine Communications. 11:103-110
Technetium-99m (99Tcm) (v) dimercaptosuccinic acid (DMSA) is a new tumour imaging agent which has been used to image medullary carcinoma of the thyroid and squamous cell carcinoma (SCC) of the head and neck. This study was undertaken to compare plana
Autor:
C. R. Lazarus
Publikováno v:
Clinical Nuclear Medicine ISBN: 9780412751806
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6753cd5bf56ff545b260747a9a82e2ef
https://doi.org/10.1007/978-1-4899-3356-0_45
https://doi.org/10.1007/978-1-4899-3356-0_45
Publikováno v:
European Journal of Nuclear Medicine. 20
Forty-seven patients, 29 with chronic inflammatory bowel disease (1131) and 18 with presumed irritable bowel syndrome, including one with uncomplicated diverticular disease, were studied with simultaneous technetium-99m hexamethylpropylene amine oxim
Publikováno v:
Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 32(6)
This study used an established rabbit tumor model with squamous carcinoma to evaluate the pharmacokinetics and biodistribution of technetium-99m-(V)dimercaptosuccinic acid. A total of 54 rabbits were studied (25 with no tumor; 29 with tumor). Technet
Publikováno v:
The Journal of laryngology and otology. 104(10)
Technetium-99m (Tc99m)(v) Dimercaptosuccinic Acid (DMSA) is animaging agent which has been proposed as a scintigraphic marker for head and neck squamous cell carcinoma. Fifty-four patients were studied of whom 51 had a head and neck tumour. All patie
Publikováno v:
Nuclear medicine communications. 11(4)
Technetium-99m (99Tcm) (v) dimercaptosuccinic acid (DMSA) is a new tumour imaging agent which has been used to evaluate head and neck tumours. It has a normal head and neck biodistribution to include the lacrimal glands, nasal mucosa and the blood-po